Author

Kelly F. Zheng

h-index 3 View on Semantic Scholar

We have 2 of 21 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

PARP1-selective inhibitor DSB1559 demonstrates superior efficacy and antitumor immunity in triple-negative breast cancer

Abstract Background Poly (ADP-ribose) polymerase inhibitors (PARPis) have improved outcomes of BRCA-associated breast cancer; however, treatment-related toxicity remains a major clinical challenge. Currently approved PARPis broadly inhibit multiple members of the PARP protein family. However, preclinical studies sugges...

Adam Nelson, Kelly F. Zheng, C. Wanderley et al. · Journal for ImmunoTherapy of... · 0 citations

Open access Sep 2026

TALAVE in Breast Cancer: BRCA1/2 Mutation-Dependent Immune Remodeling after PARP Inhibition with Limited Checkpoint Engagement

Only limited benefit of PD-1/PD-L1 blockade in augmenting PARPi activity is suggested and the need for alternative strategies to sustain PARPi-induced immunity is highlighted.

F. Lynce, Kenichi Shimada, Claudine Isaacs et al. · bioRxiv · 0 citations